BRPI0518829A2 - mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas - Google Patents

mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas

Info

Publication number
BRPI0518829A2
BRPI0518829A2 BRPI0518829-6A BRPI0518829A BRPI0518829A2 BR PI0518829 A2 BRPI0518829 A2 BR PI0518829A2 BR PI0518829 A BRPI0518829 A BR PI0518829A BR PI0518829 A2 BRPI0518829 A2 BR PI0518829A2
Authority
BR
Brazil
Prior art keywords
treatment
neuropathic pain
associated syndromes
syndromes
ibudilast
Prior art date
Application number
BRPI0518829-6A
Other languages
English (en)
Inventor
Kirk W Johnson
Lance Sultzbaugh
Jennifer Shumilla
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of BRPI0518829A2 publication Critical patent/BRPI0518829A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA O TRATAMENTO DE DOR NEUROPÁTICA E SINDROMES ASSOCIADAS. A presente invenção é dirigida ao uso de ibudilast para o tratamento de dor neuropática.
BRPI0518829-6A 2004-12-06 2005-12-06 mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas BRPI0518829A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63424804P 2004-12-06 2004-12-06
US66527605P 2005-03-25 2005-03-25
US71633305P 2005-09-12 2005-09-12
PCT/US2005/044258 WO2006063048A2 (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes

Publications (1)

Publication Number Publication Date
BRPI0518829A2 true BRPI0518829A2 (pt) 2008-12-09

Family

ID=36476178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518829-6A BRPI0518829A2 (pt) 2004-12-06 2005-12-06 mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas

Country Status (8)

Country Link
US (2) US7534806B2 (pt)
EP (1) EP1835913A2 (pt)
JP (2) JP4954085B2 (pt)
AU (1) AU2005314133B2 (pt)
BR (1) BRPI0518829A2 (pt)
CA (1) CA2587791C (pt)
MX (1) MX2007006777A (pt)
WO (1) WO2006063048A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008116720A (ru) 2005-09-26 2009-11-10 Эвиджен, Инк. (Us) Способы лечения наркозависимости и пагубных привычек в поведении
US20070191365A1 (en) * 2006-01-13 2007-08-16 Lance Sultzbaugh 3,4,6-Substituted pyridazines for treating neuropathic pain and associated syndromes
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes
EP2026804A1 (en) * 2006-05-31 2009-02-25 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
WO2007146087A2 (en) * 2006-06-06 2007-12-21 Avigen, Inc. SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE
CA2669463A1 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
EP2131841B1 (en) * 2007-01-30 2012-08-01 Avigen, Inc. Methods for treating acute pain
US20080287402A1 (en) * 2007-05-03 2008-11-20 Johnson Kirk W Use of a glial attenuator to prevent amplified pain responses caused by glial priming
CA2693697C (en) 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
CA2796280A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Topical treatments for pain
RU2459642C2 (ru) * 2010-04-27 2012-08-27 Министерство обороны Российской Федерации, Государственное образовательное учреждение высшего профессионального образования Военно-медицинская академия им. С.М. Кирова (ВМедА) Способ лечения травматических невропатий
TR201808244T4 (tr) 2010-08-04 2018-07-23 Gruenenthal Gmbh Nöropatik ağrının tedavisi için 6'-floro-(n-metil- veya n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[siklohekzan-1,1'-pirano[3,4,b]indol]-4-amin içeren farmasötik dozaj formu.
WO2012149267A1 (en) * 2011-04-27 2012-11-01 Yale University Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits
BR112017010430A2 (pt) * 2014-11-18 2017-12-26 Pixarbio Corp composição para tratar dor aguda, pós-operatória ou crônica em um indivíduo, método para tratar um indivíduo tendo dor aguda, pós-operatória ou crônica e kit para produzir a composição
BR112017010700A2 (pt) 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018102296A1 (en) * 2016-11-29 2018-06-07 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
EP3558301A4 (en) 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
JP2021512921A (ja) 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
CN112770748A (zh) 2018-10-09 2021-05-07 美迪诺亚公司 异丁司特和干扰素-β的组合及其使用方法
ES2970996T3 (es) 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
WO2020251748A1 (en) * 2019-06-11 2020-12-17 Yale University Novel treatment for wolfram syndrome
WO2021061554A1 (en) 2019-09-23 2021-04-01 Medicinova, Inc. Ibudilast oral formulations and methods of using same
CA3174413A1 (en) 2020-04-06 2021-10-14 Yuichi Iwaki Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
CN116887829A (zh) 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
EP4376838A1 (en) 2021-07-26 2024-06-05 MediciNova, Inc. Ibudilast for preventing eye cancer metastasis
CN118139619A (zh) 2021-09-21 2024-06-04 美迪诺亚公司 异丁司特以联合治疗方式用于治疗胶质母细胞瘤
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
US12171752B2 (en) 2022-02-01 2024-12-24 Medicinova, Inc. Methods of treating post-COVID condition(s)
EP4554558A1 (en) 2022-07-13 2025-05-21 MediciNova, Inc. Injectable formulations of ibudilast
WO2026060180A1 (en) 2024-09-11 2026-03-19 Medicinova, Inc. Modified release formulations of ibudilast

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
DK1106178T3 (da) * 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US7135495B2 (en) 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
EP1268474A2 (en) * 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001074860A2 (en) 2000-03-31 2001-10-11 Curagen Corporation Methods of identifying integrin ligands using differential gene expression
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
KR100884709B1 (ko) 2000-09-14 2009-02-19 미쓰비시 타나베 파마 코퍼레이션 신규한 아미드 유도체의 광학 활성체 및 그의 의약적 용도
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2002045750A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Combination drugs
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002098429A1 (en) 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
MXPA04000418A (es) * 2001-07-31 2004-03-18 Pharmacia & Up John Company Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
WO2003013513A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Stable emulsion composition
CA2456754A1 (en) 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
JPWO2003016269A1 (ja) 2001-08-09 2004-12-02 キッセイ薬品工業株式会社 ５−アミジノ−ｎ−（２−アミノフェネチル）−２−ヒドロキシベンゼンスルホンアミド誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
KR20040044856A (ko) 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
WO2003022813A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
EP1443041A4 (en) 2001-11-09 2006-06-07 Kissei Pharmaceutical 5-AMIDINO-2-HYDROXYBENZENE-SULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THEM, THEIR MEDICAL USE AND INTERMEDIATE PRODUCTS USED IN THEIR PRODUCTION
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
EP1481976B1 (en) 2002-03-05 2012-11-07 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2003090748A1 (fr) 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
WO2003092595A2 (en) 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
WO2004041164A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20060083714A1 (en) 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
EP1603933A2 (en) 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
BRPI0416812A (pt) 2003-11-21 2007-03-06 Combinatorx Inc métodos e reagentes para o tratamento de desordens inflamatórias

Also Published As

Publication number Publication date
WO2006063048A3 (en) 2006-08-24
CA2587791A1 (en) 2006-06-15
US7534806B2 (en) 2009-05-19
JP4954085B2 (ja) 2012-06-13
AU2005314133A1 (en) 2006-06-15
US20090209575A1 (en) 2009-08-20
MX2007006777A (es) 2007-08-06
JP2008522979A (ja) 2008-07-03
EP1835913A2 (en) 2007-09-26
WO2006063048A2 (en) 2006-06-15
US20060160843A1 (en) 2006-07-20
CA2587791C (en) 2012-03-13
AU2005314133B2 (en) 2012-03-08
JP2008013577A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
BRPI0518829A2 (pt) mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
BRPI0512622A (pt) uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
DE602005002066D1 (de) Vorrichtung zur Abschätzung des Hautzustandes
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
DE602004026384D1 (de) Gerät zur Hautbeobachtung
DK2151227T3 (da) Massagehoved og massageapparat, hvor dette hoved anvendes
BRPI0820519A2 (pt) intermediário para a síntese do análogo de halicondrina b e reação de dessulfonilação usada para o intermediário
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
LTC1912640I2 (lt) HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
BRPI0509211A (pt) uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética
DK1863899T3 (da) Hudbehandlingspræparater
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
DK1838318T3 (da) Anvendelse af oxycodon til behandling af visceral smerte
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.
BRPI0923688A2 (pt) compostos e métodos para o tratamento de dor e outras doenças

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.

B25B Requested transfer of rights rejected

Owner name: AVIGEN, INC (US)